House Committee on Oversight and Reform Chairwoman Carolyn Maloney (Getty Images)

House De­moc­rats call on Emer­gent ex­ecs to tes­ti­fy on qual­i­ty is­sues next month

The House Over­sight Com­mit­tee is in­ves­ti­gat­ing Covid-19 vac­cine pro­duc­er Emer­gent BioSo­lu­tions, which se­cured a $628 mil­lion US gov­ern­ment con­tract to make As­traZeneca and J&J vac­cines de­spite “a long, doc­u­ment­ed his­to­ry” of qual­i­ty con­trol is­sues, De­moc­rats said in a let­ter to the con­tract man­u­fac­tur­er’s ex­ec­u­tives.

Emer­gent’s Bal­ti­more plant, which was shut­tered on Mon­day by FDA, has been em­broiled in con­tro­ver­sy af­ter be­ing forced to de­stroy mil­lions of As­traZeneca and J&J dos­es due to an in­gre­di­ent mix-up and pos­si­ble con­t­a­m­i­na­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.